Texas Yale Capital Corp. Has $734,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Key Points

• Texas Yale Capital Corp. reduced its holdings in AstraZeneca PLC by 29.1%, resulting in ownership of 9,990 shares valued at $734,000.
• Major investors including Bank of America Corp and Franklin Resources Inc. significantly increased their stakes in AstraZeneca during the fourth quarter.
• AstraZeneca reported earnings per share of $1.24 for the last quarter, surpassing analysts' estimates and indicating a 7.2% revenue increase compared to the previous year.

Texas Yale Capital Corp. cut its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 29.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,990 shares of the company's stock after selling 4,100 shares during the period. Texas Yale Capital Corp.'s holdings in AstraZeneca were worth $734,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Capital International Investors boosted its holdings in AstraZeneca by 1.9% in the fourth quarter. Capital International Investors now owns 37,507,159 shares of the company's stock worth $2,457,706,000 after purchasing an additional 686,008 shares in the last quarter. Bank of America Corp DE boosted its holdings in AstraZeneca by 189.3% in the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after purchasing an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. boosted its holdings in AstraZeneca by 1.9% in the fourth quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock worth $1,276,367,000 after purchasing an additional 357,894 shares in the last quarter. Sanders Capital LLC boosted its holdings in AstraZeneca by 1.4% in the fourth quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock worth $995,032,000 after purchasing an additional 212,301 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in AstraZeneca by 13.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,322,388 shares of the company's stock worth $348,730,000 after purchasing an additional 636,537 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $89.00.

AstraZeneca Trading Down 1.4%

Shares of NASDAQ:AZN opened at $72.66 on Monday. The company has a market cap of $225.34 billion, a P/E ratio of 29.18, a P/E/G ratio of 1.34 and a beta of 0.37. The stock's 50-day moving average is $71.15 and its 200-day moving average is $71.17. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period last year, the business earned $2.06 earnings per share. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. Equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.